European Journal of Medical Research最新文献

{"title":"Lactate-to-albumin ratio and 28 day mortality in hypertensive patients with atrial fibrillation: a retrospective cohort study.","authors":"Rui Wu, Bo Xing, Zijun Zhou, Yuting Huang, Liming Yu, Huishan Wang","doi":"10.1186/s40001-025-03170-6","DOIUrl":"10.1186/s40001-025-03170-6","url":null,"abstract":"<p><strong>Background: </strong>The lactate-to-albumin ratio (LAR) has emerged as a composite biomarker reflecting metabolic stress and nutritional status. This study aimed to evaluate the association between the LAR and 28 day mortality in hypertensive patients with atrial fibrillation (AF).</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the MIMIC-IV v3.1 database. Patients were screened for inclusion based on predefined criteria, resulting in a final cohort of 1087 eligible patients. Mortality within 28 days of ICU admission was the primary endpoint. Statistical analyses included LASSO regression and multivariate Cox regression, receiver operating characteristic (ROC) curve, and Kaplan‒Meier survival curve analyses.</p><p><strong>Results: </strong>The overall 28 day mortality rate was 22.8% (n = 248). Compared with survivors, nonsurvivors presented significantly higher LAR values (0.74 vs. 0.52, p < 0.001). Multivariate analyses indicated that the LAR was an independent predictor of 28-day mortality (HR 1.03, 95% CI 1.01-1.06, p < 0.05), even after adjusting for multiple clinical confounders. ROC analysis confirmed that the LAR had superior predictive ability (AUC 0.661) compared with other biomarkers. Kaplan‒Meier survival analysis revealed significant differences in mortality between the high- and low-LAR groups (HR 2.55, 95% CI 1.97-3.30, p < 0.05).</p><p><strong>Conclusions: </strong>The LAR is an independent predictor of short-term mortality in hypertensive patients with AF. As a practical and easily applicable biomarker, the LAR holds significant potential for early risk stratification and tailored management in this high-risk population. Our findings underscore the importance of integrating LAR into clinical practice to optimize patient outcomes in critical care settings.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"845"},"PeriodicalIF":3.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: LCZ696 improves oxidative stress injury in human podocytes induced by increased glucose levels via Nrf2/HO-1 signaling pathway.","authors":"Hongqiang Zhang, Mingrui Yu, Yijie Zhang, Donglin Lu, Gang Liu","doi":"10.1186/s40001-025-03157-3","DOIUrl":"10.1186/s40001-025-03157-3","url":null,"abstract":"","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"844"},"PeriodicalIF":3.4,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12424199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions.","authors":"Mohammed A Abdel-Rasol, Wael M El-Sayed","doi":"10.1186/s40001-025-03073-6","DOIUrl":"10.1186/s40001-025-03073-6","url":null,"abstract":"<p><p>Nuclear receptors (NRs) are a superfamily of ligand-activated transcription factors that regulate gene expression in response to metabolic, hormonal, and environmental signals. These receptors play a critical role in metabolic homeostasis, inflammation, immune function, and disease pathogenesis, positioning them as key therapeutic targets. This review explores the mechanistic roles of NRs such as PPARs, FXR, LXR, and thyroid hormone receptors (THRs) in regulating lipid and glucose metabolism, energy expenditure, cardiovascular health, and neurodegeneration. The therapeutic landscape for NRs has expanded with the approval of drugs like PPARγ agonists (pioglitazone, rosiglitazone) for diabetes, FXR agonists (obeticholic acid) for liver diseases, and selective TR agonists (resmetirom) for Metabolic dysfunction-Associated Steatohepatitis (MASH). However, challenges such as tissue-specific activation, drug resistance in chronic diseases, and potential carcinogenic risks continue to limit the full clinical efficacy of NR-targeted therapies. Emerging therapeutic strategies, including selective nuclear receptor modulators (SNRMs), dual and pan-NR agonists, and gene therapy approaches, aim to enhance receptor specificity while minimizing adverse effects. Furthermore, advances in artificial intelligence-driven drug discovery, CRISPR-based gene therapy, and microbiome-targeted interventions hold significant promise for refining the therapeutic efficacy and safety of NR-based treatments. A deeper understanding of NR crosstalk with metabolic, inflammatory, and oncogenic pathways will be crucial for developing next-generation therapies to overcome resistance mechanisms and improve clinical outcomes. These advancements, combined with precision medicine approaches, are poised to revolutionize NR-targeted therapies, offering more precise, effective, and safer treatments for a range of metabolic, inflammatory, and oncological diseases.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"843"},"PeriodicalIF":3.4,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between maternal circulating total triiodothyronine and subsequent risk of preeclampsia.","authors":"Jiang-Nan Wu, Faustino R Pérez-López, Ignacio Rodríguez, Li Yao, Lu-Yi Mao","doi":"10.1186/s40001-025-03118-w","DOIUrl":"10.1186/s40001-025-03118-w","url":null,"abstract":"<p><strong>Introduction: </strong>To clarify the uncertain association between maternal total triiodothyronine (TT3) levels and preeclampsia risk.</p><p><strong>Methods: </strong>In a hospital-based cohort of pregnant women with universal thyroid testing, we assessed the association between TT3 and preeclampsia using directed acyclic graphs (DAG) to control confounders.</p><p><strong>Results: </strong>Maternal TT3 levels were associated with preeclampsia risk, with an adjusted odd ratio (OR) of 2.32 (95% confidence interval (CI) 2.02-2.68) in women with the highest TT3 quartile comparing to those in the lowest quartile. A J-shaped association was identified for early onset preeclampsia, with particularly strong association when thyroid-stimulating hormone exceeded 2.5 μIU/mL (OR, 17.22, 95% CI 4.52-65.60). Gestational age > 18 weeks at measurement significantly modified the effect of TT3 on preeclampsia risk, with an interaction OR of 3.22 (95% CI 1.56-6.62).</p><p><strong>Conclusion: </strong>Increased maternal TT3 levels were associated with preeclampsia. TT3 may contribute to preeclampsia pathogenesis and serve as a clinical biomarker, especially for early onset cases with thyroid dysfunction.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"842"},"PeriodicalIF":3.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning prediction of clinical pregnancy in endometriosis patients following fresh IVF/ICSI-ET.","authors":"Xiaoju Wan, Min Yu, Xingwu Wu, Zhihui Huang, Jun Tan","doi":"10.1186/s40001-025-03113-1","DOIUrl":"10.1186/s40001-025-03113-1","url":null,"abstract":"<p><strong>Background: </strong>Fresh embryo transfer reduces waiting time and minimizes embryo cryodamage for endometriosis (EM) patients. The current prediction models for fresh embryo transfer outcomes in EM primarily rely on logistic regression, with limited application of machine learning (ML) approaches. This study aimed to develop an ML-based predictive model for clinical pregnancy in EM patients undergoing fresh embryo transfer.</p><p><strong>Methods: </strong>A retrospective analysis included 1752 EM patients undergoing IVF/ICSI with fresh embryo transfer (2014-2024). Twenty-four clinical and embryonic characteristics were predictors; clinical pregnancy was the outcome. Six ML models-Naïve Bayes, Logistic Regression, Random Forest, k-Nearest Neighbors, Neural Network, and eXtreme Gradient Boosting (XGBoost)-were developed and compared. Feature selection involved logistic regression and Random Forest recursive feature elimination, with tenfold cross-validation.</p><p><strong>Results: </strong>Male age (OR = 0.96, 95% CI 0.93-0.98, p < 0.001), normal fertilization count (OR = 1.07, 95% CI 1.03-1.11, p = 0.001), and transferred embryo count (OR = 1.61, 95% CI 1.24-2.08, p < 0.001) significantly predicted clinical pregnancy. The XGBoost model demonstrated optimal performance (training AUC: 0.764; testing AUC: 0.622). Shapley Additive Explanations (SHAP) provided model interpretability.</p><p><strong>Conclusions: </strong>An XGBoost-based model effectively predicts clinical pregnancy in EM patients after fresh embryo transfer, showing acceptable performance and interpretability.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"838"},"PeriodicalIF":3.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic nomogram for hepatocellular carcinoma with major vascular invasion: a population-based study from the SEER database and a Chinese cohort.","authors":"Jia Fu, Min Liu, Sirong Chen, LiJun Chen, Shixiong Liang","doi":"10.1186/s40001-025-03110-4","DOIUrl":"10.1186/s40001-025-03110-4","url":null,"abstract":"<p><strong>Background: </strong>Patients with hepatocellular carcinoma (HCC) with major vascular invasion (MaVI) have a poor prognosis. In this study, we aimed to develop a nomogram model for predicting the prognosis of HCC with MaVI.</p><p><strong>Methods: </strong>Data of 2211 patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database on September 25, 2024. We randomly allocated the patients into training and validation cohorts using a 7:3 ratio. Furthermore, an external validation set, comprising 359 patients from Guangxi Medical University Cancer Hospital, was used. Independent variables impacting overall survival (OS) were identified using Cox regression analyses of the training cohort. The variations in OS across groups were compared using Kaplan-Meier curves and log-rank testing. A nomogram model was developed based on the identified factors. Time-dependent receiver operating characteristic curves, C-index values, decision curve analysis, and calibration curves were used to evaluate the model's predictive efficacy.</p><p><strong>Results: </strong>Independent indicators of survival for patients with HCC with MaVI included N stage, lung and bone metastases, tumor size, chemotherapy, alpha-fetoprotein (AFP) levels, radiotherapy, and surgery. A nomogram model was constructed using these factors. The C-index values were 0.73 for the training cohort, 0.72 for the internal validation cohort, and 0.72 for Chinese validation set. In training set, the area under the curve (AUC) was 0.81 (95% confidence interval [CI] 0.79-0.83), 0.80 (95% CI 0.77-0.83), and 0.79 (95% CI 0.76-0.82) at 6, 12, and 18 months, respectively. Similarly, the internal validation set had AUC of 0.83 (95% CI 0.80-0.86), 0.80 (95% CI 0.76-0.84), and 0.78 (95% CI 0.74-0.83) and the Chinese validation set had AUC of 0.85 (95% CI 0.78-0.92), 0.82 (95% CI 0.77-0.87), and 0.79 (95% CI 0.74-0.84) at 6, 12, and 18 months, respectively.</p><p><strong>Conclusions: </strong>A nomogram model based on N stage, tumor size, AFP levels, lung metastasis, bone metastasis, chemotherapy, radiotherapy, and surgery demonstrated high prediction accuracy and clinical value. Thus, it can serve as a useful reference in clinical practice for patients with HCC having MaVI.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"836"},"PeriodicalIF":3.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.","authors":"Fateme Moradi Moraddahande, Seyed Mahdi Emami Meybodi, Maryam Matin, Nafiseh Soleimani, Navid Ghasemzadeh, Ali Dehghani Firoozabadi","doi":"10.1186/s40001-025-03018-z","DOIUrl":"10.1186/s40001-025-03018-z","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) and, consequently, heart failure are life-threatening diseases, and they should be considered a worldwide health primacy. Conventional medical treatments have been unable to tackle the burden of disease thoroughly, and the limited availability of organ donors continues to pose a significant hurdle. This pressing need has prompted researchers to explore innovative regenerative techniques and expedite their progression into clinical trials, instilling fresh hope in patients who do not respond adequately to traditional therapies. Cardiac regeneration is an extensive approach that strives to repair irreversibly damaged heart tissue through groundbreaking scientific advancements, encompassing stem cells, tissue engineering, and cell-free therapies, collectively known as cardiovascular regenerative medicine (CaVaReM). The primary vision for CaVaReM is to develop regenerative-based therapies that can effectively cure cardiovascular disorders. This innovative field focuses on repairing and restoring damaged heart tissue, improving cardiac function, and ultimately enhancing the quality of life (QOL) in patients suffering from heart diseases. This review categorized cardiac regenerative therapies' present status, future opportunities, and challenges.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"837"},"PeriodicalIF":3.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NUTM2A-AS1 as a potential key regulator in cancer: unraveling its ceRNA networks and impact on tumor biology.","authors":"Negar Taghavi Pourianazar, Safa Radmehr, Zahra Ourang, Kaveh Jaseb, Alireza Asadi","doi":"10.1186/s40001-025-03019-y","DOIUrl":"10.1186/s40001-025-03019-y","url":null,"abstract":"<p><p>NUTM2A-AS1 is an emerging long noncoding RNA (lncRNA) that has garnered significant attention due to its multifaceted roles in cancer biology. As a member of the ceRNA network, NUTM2A-AS1 modulates gene expression by sequestering microRNAs, thereby influencing key oncogenic pathways. This review aims to provide a comprehensive overview of the current understanding of NUTM2A-AS1 in the development, progression, and metastasis of various cancers, including gastric cancer, hepatocellular carcinoma, neuroblastoma, colorectal cancer, glioma, lung adenocarcinoma, prostate cancer, and renal cell carcinoma. A systematic evaluation of experimental, clinical, and bioinformatics studies was conducted, with an emphasis on studies reporting expression patterns, mechanistic insights, and clinical correlations. Key findings reveal that in gastric cancer, NUTM2A-AS1 functions as a ceRNA for miR‑376a, leading to upregulation of TET1 and HIF-1A and subsequent increase in PD-L1 expression, while also modulating matrine resistance via the miR‑613/ROS/VEGFA axis. In hepatocellular carcinoma, it sponges miR‑186‑5p, thereby derepressing KLF7 and activating the Wnt/β catenin pathway. Neuroblastoma studies demonstrate that NUTM2A-AS1 enhances chemoresistance and metastasis through stabilization of B7-H3, mediated by NR1D1. In colorectal cancer, its transcriptional activation by H3K27 acetylation enables it to sequester miR-126-5p and upregulate FAM3C. Similar ceRNA-driven mechanisms involving miR-376a-3p/YAP1 in glioma, miR-590-5p/METTL3 in lung adenocarcinoma, and miR-376a-3p/PRMT5 in prostate cancer further underscore its oncogenic potential. In addition, NUTM2A-AS1 is incorporated into prognostic lncRNA signatures for renal cell carcinoma. The clinical implications of these findings are significant, as NUTM2A-AS1 holds promise as a biomarker for cancer diagnosis and prognosis and as a target for novel therapeutic strategies. Future research should prioritize in vivo studies and clinical trials, leveraging emerging technologies such as CRISPR and single-cell RNA sequencing, to fully elucidate the therapeutic potential of targeting NUTM2A-AS1 in personalized cancer treatment.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"840"},"PeriodicalIF":3.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating serum NRF2 as a screening biomarker and potential therapeutic target in diabetic foot ulcers: a prospective observational study.","authors":"Wentao Yang, Hui Cao, Song Lin, Fangtao Tian","doi":"10.1186/s40001-025-03086-1","DOIUrl":"10.1186/s40001-025-03086-1","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to investigate the relationship between serum nuclear factor erythroid 2-related factor 2 (NRF2) levels and the severity of diabetic foot ulcers (DFU) and to identify potential risk factors in severe DFU patients. Understanding this relationship could offer insights into mechanisms underlying DFU progression and inform diagnostic and therapeutic strategies.</p><p><strong>Methods: </strong>This prospective observational study included 195 DFU patients from January 2023 to May 2024, categorized into mild and severe groups using the Wagner classification system. Serum NRF2 and C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF-α) levels were measured at multiple timepoints during treatment. Statistical analyses, including logistic regression and receiver operating characteristic (ROC) curve analysis, were performed to evaluate NRF2's diagnostic value and its association with DFU severity.</p><p><strong>Results: </strong>We found that severe DFU patients had significantly lower serum NRF2 levels and higher serum IL-6, IL-17, and CRP levels compared to those in the mild group. NRF2 levels were negatively correlated with IL-6 levels. ROC curve analysis demonstrated that NRF2 was a reliable screening biomarker for severe DFU, with notable sensitivity and specificity. In addition, logistic regression identified reduced NRF2 levels as an independent risk factor for severe DFU.</p><p><strong>Conclusions: </strong>Serum NRF2 levels could serve as a valuable screening biomarker for identifying severe DFU cases. Integrating NRF2 measurements with other biomarkers could improve patient stratification and clinical outcomes. Further research is needed to validate its role and therapeutic potential in DFU management.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"841"},"PeriodicalIF":3.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between neutrophil-to-HDL cholesterol ratio and the risk of gout or hyperuricemia: evidence from NHANES 2007-2018.","authors":"Yan Ma, Junxiao Wang, Mingqi Zhang, Fengzhen Li, Zujie Qin, Jianlong Shu","doi":"10.1186/s40001-025-03106-0","DOIUrl":"10.1186/s40001-025-03106-0","url":null,"abstract":"<p><strong>Background: </strong>Neutrophil-to-HDL-C ratio (NHR) has recently emerged as a composite biomarker integrating lipid metabolism and inflammatory status. Nevertheless, its potential association with the risk of gout or hyperuricemia remains inadequately explored. The present study aimed to examine the possible link between NHR and both conditions.</p><p><strong>Methods: </strong>This study included 31,117 eligible adults from the 2007-2018 NHANES database in the United States. Participants were categorized into NHR quartiles, and weighted multivariate logistic regression along with restricted cubic spline (RCS) analyses was performed to assess its association with gout and hyperuricemia risk. Subgroup analyses were performed to assess the robustness and heterogeneity of the association across different subpopulations. All analyses were weighted to guarantee the generalizability of the findings to the national population.</p><p><strong>Results: </strong>A positive correlation was observed between NHR and the risk of both gout and hyperuricemia. As NHR levels increased, the proportion of participants with gout or hyperuricemia rose significantly-specifically, the prevalence of gout was 2.46%, 3.69%, 4.24%, and 5.79% (p < 0.001), and for hyperuricemia, it was 13.63%, 17.38%, 20.65%, and 26.08% (p < 0.001), respectively. Multivariable logistic regression indicated that, in the unadjusted Model 1 analysis, each 1-unit increase in NHR was associated with a 5.1% higher risk of gout (OR = 1.051, 95% CI 1.036-1.069, p < 0.001) and a 5.8% higher risk of hyperuricemia (OR = 1.058, 95% CI 1.051-1.066, p < 0.001). The positive association remained stable and statistically significant after adjusting for potential confounding variables. Further RCS analysis revealed a nonlinear trend in the relationship between NHR and both conditions, with a potential risk threshold of approximately 16, beyond which the risk of disease increased substantially. Additionally, receiver operating characteristic (ROC) analysis showed that the NHR had better discriminatory performance than either HDL-C or NEU alone in predicting hyperuricemia (AUC = 0.682) and gout (AUC = 0.81).</p><p><strong>Conclusion: </strong>NHR showed a significant association with the risk of gout and hyperuricemia, demonstrating a nonlinear dose-response pattern. NHR may serve as a promising inflammation-metabolism marker for the early identification of individuals at risk for uric acid-related disorders.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"839"},"PeriodicalIF":3.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}